[PDF] Top 20 When is dual bronchodilation indicated in COPD?
Has 10000 "When is dual bronchodilation indicated in COPD?" found on our website. Below are the top 20 most common "When is dual bronchodilation indicated in COPD?".
When is dual bronchodilation indicated in COPD?
... monotherapy, dual bronchodilation, and/or inhaled corticosteroids (ICSs) plus long-acting β 2 -agonists (LABAs) was identified by searching the PubMed (Medline) database for articles published in English ... See full document
15
Clinical role of dual bronchodilation with an indacaterol–glycopyrronium combination in the management of COPD: its impact on patient-related outcomes and quality of life
... of adverse events was comparable between the QVA149 group and the placebo group, ie, 57.8% and 56.6%, respec- tively. However, severe adverse events occurred in 16.4% and 10.6% of patients in the QVA149 and placebo ... See full document
10
The impact of dual bronchodilation on cardiovascular serious adverse events and mortality in COPD: a quantitative synthesis<div><br /></div>
... NCT02487446). When these results are accessible to inde- pendent researchers, closed loops might be created into the network to further improve the consistency of the indirect ... See full document
17
Clinical benefit of fixed-dose dual bronchodilation with glycopyrronium and indacaterol once daily in patients with chronic obstructive pulmonary disease: a systematic review
... A planned series of systematic searches was carried out, last updated February 2014, using the databases PubMed, EMBASE, Cochrane Central Register of Con- trolled Trials, and ClinicalTrials.gov using the following ... See full document
8
Improvement in 24-hour bronchodilation and symptom control with aclidinium bromide versus tiotropium and placebo in symptomatic patients with COPD: post hoc analysis of a Phase IIIb study
... Patient symptoms also improved following treatment. After 6 weeks, the improvement in E-RS score was greater with aclidinium compared with both placebo and tiotropium, as indicated by changes in RS-Breathlessness, ... See full document
10
<p>Absence of Adverse Effects of Tiotropium/Olodaterol Compared with the Monocomponents on Long-Term Heart Rate and Blood Pressure in Patients with Moderate-to-Very-Severe COPD</p>
... Previous analyses comparing tiotropium/olodaterol 5/5 µg with tiotropium and olodaterol monotherapies in patients par- ticipating in the TONADO ® studies showed that there were no dose- or time-related trends in QT ... See full document
10
Striving for optimal bronchodilation: focus on olodaterol
... Bronchodilator drugs are indicated for the treatment of bronchial asthma and COPD. Currently, according to the recent guidelines on the two diseases, the indications to use bronchodilators are divergent. In ... See full document
6
Dual bronchodilation vs triple therapy in the “real-life” COPD DACCORD study
... of COPD ful- filling the German COPD Disease Management Program criteria (one of which is that the diagnosis of COPD is confirmed by spirometry testing), age $40 years, and initiat- ing or changing ... See full document
12
Prevention of clinically important deteriorations in COPD with umeclidinium/vilanterol
... Deteriorations in lung function and health status could be transient or sustained. In Studies A and B, approximately half of all patients who experienced a first deterioration in lung function and a third of patients ... See full document
12
Dual bronchodilation in COPD: lung function and patient-reported outcomes – a review
... in COPD were identified, with an additional study including a post-literature search (ten for indacaterol–glycopyrronium once daily, eight for umeclidinium– vilanterol once daily, three for tiotropium–olodaterol ... See full document
28
Improving Interprofessional and Coproductive Outcomes of Care for Patients with Chronic Obstructive Pulmonary Disease
... centered COPD care and self-assessed ability to perform key skills in coproductive relationships with ...in COPD assessment as well as in patient counseling and shared decision- ...assessing COPD ... See full document
8
<p>When to use single-inhaler triple therapy in COPD: a practical approach for primary care health care professionals</p>
... Table 4 summarizes opinions among HCPs about when they would prescribe SITT to a patient with COPD. Better patient compliance emerged as the main reason: 78% of respondents either agreed or strongly agreed ... See full document
11
<p>Efficacy of tiotropium and olodaterol combination therapy on dynamic lung hyperinflation evaluated by hyperventilation in COPD: an open-label, comparative before and after treatment study</p>
... This study had an open-label, prospective, comparative before and after treatment design. Patients visiting the hospital for diagnosis and treatment of COPD who pro- vided informed consent were included in the ... See full document
10
Is inflammatory chronic obstructive pulmonary disease a coronary heart disease risk equivalent? A longitudinal analysis of the third National Health and Nutrition Examination Survey (NHANES III), 1988–1994
... matory” COPD group included mostly females ...+ COPD group had the high- est prevalence of ever smokers ...inflammatory COPD groups, however, had more current smokers than the CHD group ... See full document
12
COPD is frequent in conditions of comorbidity in patients treated with various diseases in a university hospital
... Background: Chronic obstructive pulmonary disease (COPD) is one of the leading causes of death and loss of disability-adjusted life-years. However, many COPD patients are not diagnosed because of ... See full document
5
Double bronchodilation in chronic obstructive pulmonary disease: a crude analysis from a systematic review
... Results: We analyzed 26 clinical trials conducted on 24,338 patients. All LABA/LAMA combinations were consistently able to improve lung function compared with both placebo and bronchodilator monotherapy. Improvements in ... See full document
10
Plasminogen activator inhibitor-1 is elevated in patients with COPD independent of metabolic and cardiovascular function
... in COPD could also represent a bystander effect. However, it was indicated that PAI-1 may play a plausible role in COPD, and this is the first study conducted in a well-characterized COPD ... See full document
7
The Use of Neupogen (Filgrastim) or Neulasta (Pegfilgrastim) during Pregnancy When Chemotherapy Is Indicated for Maternal Cancer Treatment
... medically indicated conditions such as previa/abrupio/ deteriorating maternal or fetal status (all noniatrogenic preterm deliveries) was compared between ... See full document
5
Relation between COPD, Smoking and Depression among Elderly Population.
... 8). COPD is a major cause of disability and death in most countries and contribute significantly to escalating health care costs ...disease, COPD ranked ninth in the world (7). It is predicted that in 2020, ... See full document
103
Diagnostic Testing for Acute Head Injury in Children: When Are Head Computed Tomography and Skull Radiographs Indicated?
... decide when to obtain head CT in children who have vomiting, amnesia, headache, drowsiness, or a history of loss of consciousness but who have none of the independent predictors that we ... See full document
10
Related subjects